FIELD: medicine, endocrinology. SUBSTANCE: method involves intravenous administration of dalargin at daily dose 4 mg in 10.0 ml of physiological solution (for 2 injections) for 10 days and repeated course for 10 days at break for 2 weeks. Method ensures to enhance tissue regeneration, phagocytosis processes, fiber formation and microcirculation. EFFECT: improved quality of treatment of patients with diabetic foot syndrome. 1 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF TREATING NEUROPATHIC TROPHIC ULCERS ACCOMPANYING DIABETIC FOOT | 2013 |
|
RU2549459C2 |
| PHARMACEUTICAL COMPOSITION FOR TREATING VASCULAR COMPLICATIONS OF DIABETES AND DIABETIC POLYNEUROPATHY | 2008 |
|
RU2381034C1 |
| METHOD OF GLYCEMIA DECREASE IN PATIENTS WITH DIABETES MELLITUS TYPE II WITH GASTRODUODENAL ULCERS | 2001 |
|
RU2192251C1 |
| METHOD OF CLOSING DEFECTS OF LOW-INTENSITY WOUNDS OF LOWER EXTREMITIES IN DIABETIC FOOT SYNDROME | 2015 |
|
RU2608431C1 |
| METHOD OF TREATING DIABETES MELLITUS IN COMPLEX WITH DALARGIN | 2023 |
|
RU2816021C1 |
| METHOD FOR SOFT TISSUES DEFECTS TREATMENT IN PATIENTS WITH DIABETIC FOOT SYNDROME | 2016 |
|
RU2619257C1 |
| METHOD FOR TREATING DIABETIC FOOT SYNDROME BEFORE FORMATION OF ULCEROUS DEFECT USING EXTRACORPORAL SHOCK WAVE THERAPY | 2016 |
|
RU2632683C1 |
| PERSISTENT WOUND HEALING APPROACH IN PATIENTS SUFFERING FROM PANCREATIC DIABETES | 2008 |
|
RU2358757C1 |
| METHOD OF DIAGNOSIS OF DIABETIC FOOT SYNDROME | 2021 |
|
RU2750361C1 |
| METHOD FOR DETERMINING PROGNOSIS OF WOUND DEFECT HEALING IN DIABETIC FOOT SYNDROME | 2020 |
|
RU2742760C1 |
